MRGPRX2 activation as a rapid, high-throughput mechanistic-based approach for detecting peptide-mediated human mast cell degranulation liabilities

by Marc A. Lafleur, Jonathan Werner, Madeline Fort, Edward K. Lobenhofer, Mercedesz Balazs, Ana Goyos
Published 2020-01-01

627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer

by Keegan Cooke, Jinghui Zhan, Juan Estrada, Marie-Anne Damiette Smit, Aditya Shetty, Jonathan Werner, Fei Lee
Published 2020-11-01

Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro

by Hamid R. Amouzadeh, Isaiah Dimery, Jonathan Werner, Gataree Ngarmchamnanrith, Michael J Engwall, Hugo M. Vargas, Deborah Arrindell
Published 2019-10-01